From a sustainability perspective, the situation involving Allergan and Valeant Pharmaceuticals presents an interesting issue. While we recognize the merit in Valeant’s acquisitive strategy, to gain control of strong free cash flow products while also dispensing with R&D expenses to boost margins and profitability, from a sustainability standpoint we question whether this hurts stakeholders over the long run.
As a standalone company, Allergan has delivered solid financial returns as well as maintaining its commitment to transparency and sustainable operations. The company has been an early adopter of sustainability reporting since 1992 and has done a thorough job over the years of keeping investors informed of safety, energy consumption, and waste generation trends as well as publishing its comprehensive annual sustainability performance report. It is an organization that understands its role not only in the context of its own industry, but also as a player in a broader global community. Here’s a snapshot of their sustainability goals going out to 2020.
Some of these initiatives translate directly to the financial bottom line, i.e., a reduction of waste and energy usage, while other initiatives aid in boosting worker productivity and mitigating future risks. The company also makes a commitment to become more involved in the communities in which they operate.
All of this is in stark contrast with Valeant’s culture. Taking a deeper look at Valeant’s website we were unable to locate any evidence of sustainability reporting or signs of a commitment to the broader aspects of ESG. They certainly fell far short when compared to the information and commitment provided by Allergan and its CEO. We strongly suspect this degree of ESG awareness will be thrown to the wayside if the Valeant takeover goes through and would pose the question of which is the better outcome for all stakeholders in the long run. What would be lost if the company’s sustainability goals no longer have relevance under new management?
We would appreciate any comments and invite others to contribute to the conversation.
Andrew Friedman, CFP®
AJF Financial Services, Inc.
708 Third Ave., Suite 2011
New York, NY 10017
Securities offered through American Portfolios Financial Services, Inc. (APFS) Member FINRA/SIPC. AJF Financial Services, Inc. is not affiliated with APFS.
Information in this illustration has been obtained from sources believed to be reliable and are subject to change without notification. The information presented is provided for informational purposes only and not to be construed as a recommendation or solicitation. Investors must make their own determination as to the appropriateness of an investment or strategy based on their specific investment objectives, financial status and risk tolerance. Past performance is not an indication of future results. Investments involve risk and the possible loss of principal.
Check the background of your financial professional on FINRA's BrokerCheck.
The content is developed from sources believed to be providing accurate information. The information in this material is not intended as tax or legal advice. Please consult legal or tax professionals for specific information regarding your individual situation. Some of this material was developed and produced by Advisor Launchpad to provide information on a topic that may be of interest. Advisor Launchpad is not affiliated with the named representative, broker-dealer, state- or SEC-registered investment advisory firm. The opinions expressed and material provided are for general information, and should not be considered a solicitation for the purchase or sale of any security.